Comparison of glucose time in range and area under curve in range in relation to risk of diabetic retinopathy in type 2 diabetes patients

Relationship Between Core Continuous Glucose Monitoring Metrics, including Time in Range, and Cardiovascular Autonomic Neuropathy in Outpatients with Type 2 Diabetes

(2021) Min Young Kim et al.   Diabetes Technology & Therapeutics

Profiles of Intraday Glucose in Type 2 Diabetes and Their Association with Complications: An Analysis of Continuous Glucose Monitoring Data

(2021) Jithin Sam Varghese et al.   Diabetes Technology & Therapeutics

American Association of Clinical Endocrinology Clinical Practice Guideline: The Use of Advanced Technology in the Management of Persons With Diabetes Mellitus

(2021) George Grunberger et al.   Endocrine Practice

Relationship between time in range, glycemic variability, HbA1c and complications in adults with type 1 diabetes mellitus

(2021) Anass El Malahi et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Time in Range, as a Novel Metric of Glycemic Control, Is Reversely Associated with Presence of Diabetic Cardiovascular Autonomic Neuropathy Independent of HbA1c in Chinese Type 2 Diabetes

(2020) Qingyu Guo et al.   Journal of Diabetes Research

Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease

(2020) Laura Mayeda et al.   BMJ Open Diabetes Research & Care

Association Between Continuous Glucose Monitoring-Derived Time in Range, Other Core Metrics, and Albuminuria in Type 2 Diabetes

(2020) Jee Hee Yoo et al.   Diabetes Technology & Therapeutics

Comparison of Multiple Cut Points for Time in Range in Relation to Risk of Abnormal Carotid Intima-Media Thickness and Diabetic Retinopathy

(2020) Jingyi Lu et al.   DIABETES CARE

Relationships between time in range, glycemic variability including hypoglycemia and types of diabetes therapy in Japanese patients with type 2 diabetes mellitus: Hyogo Diabetes Hypoglycemia Cognition Complications study

(2020) Norihiro Kuroda et al.   Journal of Diabetes Investigation

Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study

(2020) Jingyi Lu et al.   DIABETES CARE

Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control

(2018) Tonya D. Riddlesworth et al.   Diabetes Technology & Therapeutics

Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes

(2018) Jingyi Lu et al.   DIABETES CARE

Glucose Management Indicator (GMI): A New Term for Estimating A1C From Continuous Glucose Monitoring

(2018) Richard M. Bergenstal et al.   DIABETES CARE

Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials

(2018) Roy W. Beck et al.   DIABETES CARE

Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial

(2018) Stephen N. Davis et al.   DIABETES CARE

Metrics for glycaemic control — from HbA1c to continuous glucose monitoring

(2017) Boris P. Kovatchev   Nature Reviews Endocrinology

Mortality in Type 1 Diabetes in the DCCT/EDIC Versus the General Population

(2016)   DIABETES CARE

Optimal Sampling Intervals to Assess Long-Term Glycemic Control Using Continuous Glucose Monitoring

(2011) Dongyuan Xing et al.   Diabetes Technology & Therapeutics